

# Zonisamid als Antiepileptikum

Andreas Schulze-Bonhage und Thomas J. Feuerstein, Freiburg

## Literatur

- World Health Organization, 2001. Fact Sheet No. 165. Epilepsy: epidemiology, etiology and prognosis. Available at <http://www.who.int/mediacentre/factsheets/fs165/en>.
- Masuda Y, Karasawa T, Shiraisi Y, et al. 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacol profile. *Arzneimittelforsch* 1980;30:477–83.
- Wada Y, Hasegawa H, Okuda H, Yamaguchi N. Effect of a novel anticonvulsant, zonisamide (AD-810, CI-912) in an experimental model of photosensitive epilepsy. *Epilepsy Research* 1990;7:117–20.
- Nagatomo I, Akasaki Y, Hashiguchi W, et al. A solvent used for antiepileptic drugs increases serum and brain zonisamide concentration in seizure-susceptible El mice. *Epilepsy Behav* 2001;2:357–62.
- Hamada K, Ishida S, Yagi K, Seino M. Anticonvulsant effects of zonisamide on amygdaloid kindling in rats. *Neurosciences* 1990;16:407–12.
- Ito T, Hori M, Masuda Y, et al. 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug: electroencephalographic profile. *Arzneimittelforschung/Drug Res* 1980;30:603–9.
- Kamai C, Oka M, Masuda Y, et al. Effects of 3-sulfamoylmethyl-1,2-benzisoxazole (AD-810) and some antiepileptics on the kindled seizures in the neocortex, hippocampus and amygdala in rats. *Arch Int Pharmacodyn Ther* 1981;249:164–76.
- Wada Y, Hasegawa H, Okuda H, Yamaguchi N. Anticonvulsant effects of zonisamide and phenytoin on seizure activity of the feline visual cortex. *Brain Dev* 1990;12:206–10.
- Hori M, Ito T, Yoshida K, Shimizu M. Effect of anticonvulsants on spiking activity induced by cortical freezing in cats. *Epilepsia* 1979;20:25–36.
- Ito T, Hori M, Yoshika K, Shimizu M. Effect of anticonvulsants on experimental cortical epilepsy induced by tungstic acid gel in rats. *Arch Int Pharmacodyn* 1979;241:287–99.
- Ito T, Hori M, Kadokawa T. Effect of zonisamide (AD-810) on tungstic acid gel-induced thalamic generalized seizures and conjugated estrogen-induced cortical spike-wave discharges in cats. *Epilepsia* 1986;27:367–74.
- Schauf CL. Zonisamide enhances slow sodium inactivation in *Myxicola*. *Brain Res* 1987;413:185–8.
- Rock DM, Macdonald RL, Taylor CP. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. *Epilepsy Res* 1989;3:138–43.
- Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. *Epilepsy Res* 1992;12:21–7.
- Kito M, Maehara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. *Seizure* 1996;5:115–9.
- Kawai M, Hiramatsu M, Endo A, et al. Effect of zonisamide on release of aspartic acid and gamma-aminobutyric acid from hippocampal slices of El mice. *Neurosciences* 1994;20:115–9.
- Okada M, Kaneko S, Hirano T, et al. Effects of zonisamide on dopaminergic system. *Epilepsy Res* 1995;22:193–203.
- Okada M, Kawata Y, Mizuno K, et al. Interaction between Ca<sup>2+</sup>, K<sup>+</sup>, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. *Br J Pharmacol* 1998;124:1277–85.
- Okada M, Hirano T, Kawata Y, et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. *Epilepsy Res* 1999;34:187–97.
- Ueda Y, Doi T, Tokumaru J, Willmore LJ. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. *Mol Brain Res* 2003;116:1–6.
- Hammond EJ, Perchalski RJ, Wilder BJ, McLean JR. Neuropharmacology of zonisamide, a new antiepileptic drug. *Gen Pharmacol* 1987;18:303–7.
- Masuda V, Karasawa T. Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. *Arzneimittelforschung/Drug Res* 1993;4:416–7.
- Seino M, Fujitani B. Zonisamide: clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrum BS, Perucca E (eds.). *Antiepileptic Drugs*. 5<sup>th</sup> edition. Philadelphia: Lippincott Williams & Wilkins, 2002: 885–91.
- Komatsu M, Okamura Y, Hiramatsu M. Free radical scavenging activity of zonisamide and its inhibitory effect on lipid peroxide formation in iron-induced epileptogenic foci of rats. *Neurosciences* 1995;21:23–9.
- Mori A, Noda Y, Packer L. The anticonvulsant zonisamide scavenges free radicals. *Epilepsy Res* 1998;30:153–8.
- Peters DH, Sorkin EM. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. *Drugs* 1993;45:760–87.
- Matsumoto K, Miyezaki H, Fujii T, et al. Absorption, distribution and excretion of 3-(sulfamoyl[14C]-methyl)-1,2-benzisoxazole (AD-810) in rats, dogs, and monkeys and of AD-810 in man. *Arzneimittelforschung* 1983;33:961–8.
- Seino M, Naruto S, Ito T, Miyazaki H. Other antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS (eds.). *Antiepileptic drugs*. 4<sup>th</sup> edition. New York: Raven Press, 1995:1011.
- Shimoyama R, Ohkubo T, Sugawara K. Monitoring of zonisamide in human breast milk and maternal plasma by solid-phase extraction HPLC method. *Biomed Chromatogr* 1999;13:370–2.
- Berry DJ. Determination of zonisamide (3-sulfamoylmethyl-1,2-benzisoxazole) in plasma at therapeutic concentrations by high-performance liquid chromatography. *J Chromatogr* 1990;534:173–81.
- Kalbe K, Nishimura S, Ishii H, Sunahara N, et al. Competitive binding enzyme immunoassay for zonisamide, a new antiepileptic drug, with selected paired-enzyme labeled antigen and antibody. *Clin Chem* 1990;36:24–7.
- Ito T, Yamaguchi T, Miyazaki H, Sekine Y, et al. Pharmacokinetic studies of AD-810, a new antiepileptic compound. Phase I trials. *Arzneimittelforschung* 1982;32:1581–6.
- Kimura M, Tanaka N, Kimura Y, et al. Pharmacokinetic interaction of zonisamide in rats: effect of other antiepileptics on zonisamide. *J Pharmacobiol Dyn* 1992;15:631–9.
- Shinoda M, Akita M, Hasegawa M, et al. The necessity of adjusting the dosage of zonisamide when coadministered with other anti-epileptic drugs. *Biol Pharmacol Bull* 1996;19:1090–2.
- Ojemann LM, Shastri RA, Wilensky AJ, et al. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. *Ther Drug Monit* 1986;8:293–6.
- Sackellares JC, Donofrio PD, Wagner JG, et al. Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in patients with

---

*Priv.-Doz. Dr. med. Andreas Schulze-Bonhage, Leiter des Epilepsiezentrums am Universitätsklinikum Freiburg, Breisacher Str. 64, 79106 Freiburg, E-Mail: schulzeb@nz.ukl.uni-freiburg.de Prof. Dr. Thomas J. Feuerstein, Sektion Neuropharmakologie, Universitätsklinikum Freiburg, Breisacher Str. 64, 79106 Freiburg*

- refractory partial seizures. *Epilepsia* 1985;26:206–11.
37. McJilton J, DeToledo J, DeCerce J, et al. Cotherapy of lamotrigine/zonisamide results in significant elevation of zonisamide levels. *Epilepsia* 1996;37(S5):173.
  38. Wilson EA, Brodie MJ, Smith D, et al. Lack of pharmacokinetic interaction between steady-state zonisamide and lamotrigine in patients with epilepsy. Poster presented at the 26th International Epilepsy Congress, Paris 2005
  39. Matsumoto K, Miyezaki H, Fujii T, et al. Binding of sulfonamides to erythrocyte proteins and possible drug-drug interaction. *Chem Pharmacol Bull* 1989;37:2807–10.
  40. Mather GG, Shah J. Zonisamide: Drug interactions. In: Levy RH, Mattson RH, Meldrum BS, Perucca E (eds.). *Antiepileptic Drugs*. 5<sup>th</sup> edition. Philadelphia: Lippincott Williams & Wilkins, 2002:880–4.
  41. Chadwick D, Marson A. Zonisamide add-on for drug-resistant partial epilepsy. *Cochrane Database Syst Rev* 2005;4:CD001416.
  42. Faught E, Ayala R, Montouris GG, et al. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. *Neurology* 2001;57:1774–9.
  43. Sackellaris JC, Ramsay E, Wilder BJ, et al. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. *Epilepsia* 2004;45:610–7.
  44. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. *Epilepsy Res* 1993;15:67–73.
  45. Brodie MJ, Duncan R, Verpignani H, et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. *Epilepsia* 2005;46:31–41.
  46. Marmarou A, Pellock JM. Zonisamide: Physician and patient experiences. *Epilepsy Res* 2005;64:63–9.
  47. Yagi K, Seino M. Methodological requirements for clinical trials in refractory epilepsies: our experience with zonisamide. *Prog Neuropsychopharmacol Biol Psychiatr* 1992;16:79–85.
  48. Leppik IE, Willmore LJ, Homan RW, et al. Efficacy and safety of zonisamide: results of a multicenter study. *Epilepsy Res* 1993;14:165–73.
  49. Browne TR, Leppik IE, Penry JK, et al. Zonisamide efficacy in long term studies. *Epilepsia* 1997;38(S8):108.
  50. Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese experience. *J Child Neurol* 2002;17:87–96.
  51. Linuma K, Haginoya K. Clinical efficacy of zonisamide in childhood epilepsy after long-term treatment: a postmarketing, multi-institutional survey. *Seizure* 2004;135:534–9.
  52. Lotze TE, Wilfong AA. Zonisamide treatment for symptomatic infantile spasms. *Neurology* 2004;62:296–8.
  53. Mandelbaum DE, Bunch M, Kugler SL, et al. Broad-spectrum efficacy of zonisamide at 12 months in children with intractable epilepsy. *J Child Neurol* 2005;20:594–7.
  54. Seki T, Kumagai N, Maezawa M. Effect of zonisamide monotherapy in children with epilepsy. *Seizure* 2004;135:S26–S32.
  55. Wilfong AA. Zonisamide monotherapy for epilepsy in children and young adults. *Pediatr Neurol* 2005;32:77–80.
  56. Leppik IE, Gumnit RJ, Jacobs MP, Henry T. Intractable myoclonic seizures treated with zonisamide. *Neurology* 1986;Vol. Nr.?(S36):326.
  57. Henry TR, Leppik IE, Gumnit RJ, Jacobs M. Progressive myoclonus epilepsy treated with zonisamide. *Neurology* 1988;38:928–31.
  58. Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonic epilepsy: long-term observations in seven patients. *Epilepsy Res* 1998;29:109–14.
  59. Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. *Epilepsy Res* 1998;29:147–54.
  60. Yoshimura I, Kaneko S, Yoshimura N, Murakami T. Long-term observations of two siblings with Lafora disease treated with zonisamide. *Epilepsy Res* 2001;46:283–7.
  61. Santos C, Brotherton T. Myoclonic and atonic seizures: response to zonisamide in pediatric patients. *Epilepsia* 2002;43(S7):199.
  62. Smith MC, Hershkowitz L, Beulow JM, et al. Zonisamide therapy in frontal lobe or progressive myoclonic epilepsy. *Epilepsia* 2002;43(S7):200.
  63. Andriola MR, Miller MA, Vitale SJ, et al. Zonisamide as adjunctive and monotherapy in absence epilepsy. *Epilepsia* 2002;43(S7):190.
  64. Hershkowitz L. Zonisamide therapy in patients with absence seizures. *Epilepsia* 2002;43(S7):193.
  65. Schultz R, Wilfong A. Use of zonisamide in patients with absence seizures: a retrospective chart review. *Epilepsia* 2003;44(S9):271–2.
  66. Wilfong A, Schultz R. Zonisamide for absence seizures. *Epilepsy Res* 2005;64:31–4.
  67. Yamatogi Y, Othahara S. Current topics of treatment. In: Othahara S, Roger J (eds.). *Proceedings of the international symposium new trends in pediatric epileptology*. Okayama: U Med School, 1991:136–48.
  68. Santos C, Brotherton T. Zonisamide associated with seizure freedom in pediatric patients with lennox-gastaut syndrome. *Epilepsia* 2003;44(S9):112.
  69. Talwar D, Akhtar N. Clinical and electroencephalogram improvements in pediatric patients with zonisamide. *Epilepsia* 2002;43(S7):201.
  70. Lee BI. Zonisamide: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E (eds.). *Antiepileptic Drugs*. 5<sup>th</sup> edition. Philadelphia: Lippincott Williams & Wilkins, 2002:892–8.
  71. Berent S, Sackellaris JC, Giordani B, et al. Zonisamide (CI-912) and cognition: results from a preliminary study. *Epilepsia* 1987;28:61–7.
  72. Charles CL, Stoesz L, Tollefson G. Zonisamide-induced mania. *Psychosomatics* 1990;31:214–7.
  73. Kimura S. Zonisamide-induced behaviour disorder in two children. *Epilepsia* 1994;35:403–5.
  74. Miyamoto T, Kohsaka M, Koyama T. Psychotic episodes during zonisamide treatment. *Seizure* 2000;9:65–70.
  75. Low PA, James S, Peschel T, Leong R, et al. Zonisamide and associated oligohydrosis and hyperthermia. *Epilepsy Res* 2004;62:27–34.
  76. Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. *Epilepsia* 1996;37:1242–4.
  77. Kochak GM, Page JG, Buchanan RA, Peters R, et al. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. *J Clin Pharmacol* 1998;38:166–7.
  78. Endoh A, Kinno I, Kawai M, Hiramatsu M, et al. Effects of zonisamide on neurotransmitter in the mouse brain. *Neurosciences* 1994;20:173–6.
  79. Mizuno K. Effects of carbamazepine and zonisamide on acetylcholine levels in rat striatum. *Nihon Shinkei Seisin Yakurigaku Zashi* 1997;17:17–23.